Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(157 prodotti)
- Bcr-Abl(113 prodotti)
- EGFR(596 prodotti)
- FAK(72 prodotti)
- FLT(88 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(180 prodotti)
- JAK(246 prodotti)
- PDGFR(126 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(52 prodotti)
- VDA(2 prodotti)
- VEGFR(250 prodotti)
Mostrare 6 più sottocategorie
Trovati 2002 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-42
EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.Formula:C49H53ClFN5O5Colore e forma:SolidPeso molecolare:846.43PROTAC BCR-ABL Degrader-1
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway andFormula:C43H40N10O6Purezza:98%Colore e forma:SolidPeso molecolare:792.84VEGFR2/HDAC1-IN-1
VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.Purezza:98%Colore e forma:Odour SolidAKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Formula:C17H14N6Purezza:99.88%Colore e forma:SolidPeso molecolare:302.33Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formula:C50H48N12O4Purezza:98%Colore e forma:SolidPeso molecolare:880.99Bevasiranib
CAS:Bevasiranib is a siRNA targeting VEGF production, key in choroidal neo-vascularization and wet AMD.Colore e forma:SolidEGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Formula:C22H17F3N4OPurezza:98%Colore e forma:SolidPeso molecolare:410.39DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Colore e forma:LiquidSJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purezza:98%Colore e forma:SolidPeso molecolare:797.3PF15
CAS:PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Formula:C44H49N13O6Purezza:98%Colore e forma:SolidPeso molecolare:855.94AD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formula:C22H20F3N7OPurezza:99.05%Colore e forma:SoildPeso molecolare:455.44Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Formula:C56H80N12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1097.39TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Colore e forma:Odour SolidALK protein ligand-1
CAS:ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.Formula:C24H29ClN6O3SColore e forma:SolidPeso molecolare:517.043EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Formula:C26H20ClFN4OSColore e forma:SolidPeso molecolare:490.98BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Colore e forma:Odour SolidhCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Formula:C21H17FN6O3SPurezza:98%Colore e forma:SolidPeso molecolare:452.46PROTAC EGFR degrader 6
CAS:<p>PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.</p>Formula:C49H57FN12O5Colore e forma:SolidPeso molecolare:913.05SJ10542
CAS:SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.Formula:C41H46N12O5SColore e forma:SolidPeso molecolare:818.95EGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Formula:C20H17Cl2N3O3Colore e forma:SolidPeso molecolare:418.273Lyn peptide inhibitor
CAS:Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.Formula:C115H184N30O24Purezza:98%Colore e forma:SolidPeso molecolare:2370.91SIAIS164018 hydrochloride
<p>SIAIS164018 hydrochloride is a PROTAC-based degrader targeting ALK and EGFR, exhibiting IC50 values of 2.5 nM for ALK and 6.6 nM for ALK G1202R.</p>Formula:C43H49Cl2N10O7PPurezza:98%Colore e forma:SolidPeso molecolare:919.79ALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Formula:C29H39ClN7O2PColore e forma:SolidPeso molecolare:584.1Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formula:C63H107N19O20S2Purezza:98%Colore e forma:SolidPeso molecolare:1514.77DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Colore e forma:Odour SolidMS9427 TFA
MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.Formula:C50H59ClF4N8O14Colore e forma:SolidPeso molecolare:1107.5Duligotuzumab
CAS:Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.Purezza:97.7% (SDS-PAGE); 96.3% (SEC-HPLC) - ≥95% (SDS-PAGE); 95.19% (SEC-HPLC)Colore e forma:LiquidBW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Formula:C28H29FN6O2SColore e forma:SolidPeso molecolare:532.63FLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Formula:C20H22FN5O2Colore e forma:SolidPeso molecolare:383.42(R)-3-Hydroxy Midostaurin
CAS:(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.Formula:C35H30N4O5Purezza:98%Colore e forma:SolidPeso molecolare:586.648SOS1/EGFR-IN-2
SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.Formula:C25H29F3N4O3Colore e forma:SolidPeso molecolare:490.52SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFormula:C60H77ClN12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1177.85Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Formula:C33H34N4O3Colore e forma:SolidPeso molecolare:534.648CS-VIP 8 TFA
CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.Formula:C45H53F7N12O9Colore e forma:SolidPeso molecolare:1038.39467DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Formula:C55H62N10O8Colore e forma:SolidPeso molecolare:991.163EGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Formula:C20H17FN6O2S2Colore e forma:SolidPeso molecolare:456.52JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formula:C30H33FN4O3SColore e forma:SolidPeso molecolare:548.67Si5-N14
CAS:Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.Formula:C78H160N6O5Si2Colore e forma:SolidPeso molecolare:1318.31ALK/ROS1-IN-5
<p>ALK/ROS1-IN-5 (compound X4) is a selective inhibitor of ALK and ROS1 kinases, with IC50 values of 0.512 μM for ALK and 0.766 μM for ROS1. It inhibits H2228 cells with an IC50 of 0.034 μM and induces apoptosis in cancer cells in a dose-dependent manner. Additionally, ALK/ROS1-IN-5 effectively suppresses the expression of p-ALK and p-ERK in cancer cells.</p>Formula:C32H28F2N4O3Colore e forma:SolidPeso molecolare:554.586FAK-IN-9
CAS:FAK-IN-9 (8f) is a potent oral FAK inhibitor, IC50 of 27.44 nM; induces TNBC cell apoptosis.Formula:C36H38ClN7O8SColore e forma:SolidPeso molecolare:764.25EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Formula:C17H15N7O5SColore e forma:SolidPeso molecolare:429.41SA-PA
SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cellsFormula:C40H32ClF3N10O8Purezza:98%Colore e forma:SolidPeso molecolare:873.19JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formula:C22H23FN4O3SColore e forma:SolidPeso molecolare:442.51MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Formula:C25H29ClN8O2Colore e forma:SolidPeso molecolare:509OK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Formula:C42H62N14O9Purezza:98%Colore e forma:SolidPeso molecolare:907.03Cetuximab (PBS)
Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.Colore e forma:Odour LiquidScr-IN-1
Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.Formula:C26H16ClF3N2O3Colore e forma:SolidPeso molecolare:496.87MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formula:C48H58ClFN8O12Colore e forma:SolidPeso molecolare:993.47EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Formula:C27H31N3O2Colore e forma:SolidPeso molecolare:429.24163EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purezza:98%Colore e forma:SolidPeso molecolare:468.55DD0-2363
<p>DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.</p>Formula:C36H36ClFN6O4Colore e forma:SolidPeso molecolare:671.16EGFR/BRAFV600E-IN-4
<p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>Formula:C22H16N4OSColore e forma:SolidPeso molecolare:384.45Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Purezza:98%Colore e forma:Odour SolidALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Formula:C24H30ClN6O2PColore e forma:SolidPeso molecolare:500.97FGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Formula:C36H42N12O6Colore e forma:SolidPeso molecolare:738.33503Erlotinib-13C6
CAS:Erlotinib-13C6 (CP-358774-13C6), a 13C-labeled direct EGFR inhibitor, IC50: 2 nM.Formula:C22H23N3O4Colore e forma:SolidPeso molecolare:399.3972-Keto Crizotinib
CAS:2-Keto Crizotinib is an active lactam metabolite of crizotinib.Formula:C21H20Cl2FN5O2Purezza:98%Colore e forma:SolidPeso molecolare:464.32Amuvatinib hydrochloride
CAS:Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formula:C23H22ClN5O3SPurezza:98%Colore e forma:SolidPeso molecolare:483.97BCR-ABL-IN-3
CAS:BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.Formula:C20H17ClF2N4O3SColore e forma:SolidPeso molecolare:466.89Verucopeptin
CAS:Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.Formula:C43H73N7O13Colore e forma:SolidPeso molecolare:896.08TL13-12
CAS:TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).Formula:C45H53ClN10O10SPurezza:98%Colore e forma:SolidPeso molecolare:961.49PROTAC EGFR degrader 10
CAS:PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.Formula:C49H65ClN10O7SColore e forma:SolidPeso molecolare:973.62Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Colore e forma:Odour LiquidTL13-110
CAS:Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Formula:C49H62ClN9O9SColore e forma:SolidPeso molecolare:988.59HER2-IN-14
CAS:HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Formula:C26H23ClF2N8O3Colore e forma:SolidPeso molecolare:568.96PROTAC EGFR degrader 8
CAS:<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Formula:C40H46ClN11O5Purezza:98%Colore e forma:SolidPeso molecolare:796.32SC209
CAS:SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.Formula:C27H44N4O4Colore e forma:SolidPeso molecolare:488.66Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurezza:99.94%Colore e forma:SolidPeso molecolare:256.12BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Colore e forma:SolidPeso molecolare:527.508MTX-241F
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.Formula:C20H14ClFN6Purezza:98%Colore e forma:SolidPeso molecolare:392.82PST3.1a
CAS:PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).Formula:C32H33O6PColore e forma:SolidPeso molecolare:544.57EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Formula:C23H32BrN7O2SPurezza:98%Colore e forma:SolidPeso molecolare:550.51DSPE-PEG1000-A7R
DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Colore e forma:Odour SolidML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Formula:C47H53BrCl2N10O7SPurezza:98%Colore e forma:SolidPeso molecolare:1052.86Tomuzotuximab
CAS:<p>Tomuzotuximab: fully human, glycoengineered IgG1 anti-EGFR monoclonal antibody with anticancer properties.</p>Colore e forma:LiquidEGFR/HER2/DHFR-IN-2
<p>EGFR/HER2/DHFR-IN-2 (Compound 4b) serves as an inhibitor for EGFR, HER2, and DHFR, with IC50 values of 0.248, 0.156, and 0.138 μM, respectively.</p>Purezza:98%Colore e forma:Odour SolidEGFR-IN-120
EGFR-IN-120 (Compound 11eg) is an orally effective EGFR inhibitor. It exhibits potency against the EGFR L858R/T790M/C797S mutant with an IC50 of 0.053 μM, and displays weaker activity against EGFRWT, with an IC50 of 1.05 μM. EGFR-IN-120 inhibits the phosphorylation of EGFR as well as key downstream effectors including STAT3, AKT, and Erk. This compound induces cell cycle arrest and apoptosis in cells harboring the EGFR mutation. Additionally, EGFR-IN-120 inhibits the proliferation of NSCLC cells containing the EGFR L858R/T790M/C797S mutation, with an IC50 value of 0.052 μM.Colore e forma:Odour SolidPROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Formula:C49H64ClFN10O7SColore e forma:SolidPeso molecolare:991.61Varlitinib Tosylate
CAS:Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Formula:C36H35ClN6O8S3Purezza:98%Colore e forma:SolidPeso molecolare:811.34Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS:Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Formula:C51H65N17O19P2S2·xC6H15NColore e forma:SolidPeso molecolare:1447.44Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Formula:C36H35FN6O10Colore e forma:SolidPeso molecolare:730.696hCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII andFormula:C23H26N6O5SPurezza:98%Colore e forma:SolidPeso molecolare:498.55SJ988497
CAS:SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.Formula:C36H36N10O5Colore e forma:SolidPeso molecolare:688.74CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurezza:98%Colore e forma:SolidPeso molecolare:961.18hCA/VEGFR-2-IN-4
hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/Formula:C22H23FN6O5SPurezza:98%Colore e forma:SolidPeso molecolare:502.52PACAP-38 (31-38), human, mouse, rat TFA
PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.Formula:C49H84F3N17O13Purezza:98%Colore e forma:SolidPeso molecolare:1176.29Istiratumab
CAS:Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.Colore e forma:LiquidCaffeic acid-pYEEIE
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).</p>Formula:C39H50N5O19PPurezza:98%Colore e forma:SolidPeso molecolare:923.82HG-7-85-01
CAS:<p>HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.</p>Formula:C31H31F3N6O2SPurezza:98.08%Colore e forma:SolidPeso molecolare:608.68GSK143
CAS:GSK143: Oral SYK inhibitor, pIC50=7.5, curbs pErk, anti-inflammatory, hinders immune cells in mice.Formula:C17H22N6O2Colore e forma:SolidPeso molecolare:342.403IMC-D11
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.Colore e forma:Odour LiquidVislarafusp alfa
Vislarafusp alfa is a humanized IgG1κ antibody that targets EGFR/CD47, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.Colore e forma:Odour LiquidAntifibrotic agent 1
Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.Formula:C27H23ClN6O2Colore e forma:SolidPeso molecolare:498.1571SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFormula:C43H45N13O9SPurezza:98%Colore e forma:SolidPeso molecolare:919.96E7090
CAS:<p>E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.</p>Formula:C32H37N5O6Colore e forma:SolidPeso molecolare:587.67IOX2-NH2-Methyl
<p>IOX2-NH2-Methyl is a modified form of IOX2. IOX2 is a specific inhibitor of PHD2 (prolyl-hydroxylase-2), capable of upregulating HIF-1α expression and suppressing ROS production. IOX2-NH2-Methyl is employed in investigations of platelet and thrombus formation.</p>Formula:C20H19N3O5Purezza:97.64% - 99.31%Colore e forma:SolidPeso molecolare:381.39SJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Formula:C57H61ClFN7O9SPurezza:99.20%Colore e forma:SolidPeso molecolare:1074.65hCA/VEGFR-2-IN-3
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.Formula:C24H28N6O6SPurezza:98%Colore e forma:SolidPeso molecolare:528.58MLK3-IN-1
<p>MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.</p>Formula:C20H16F6N4O2SColore e forma:SolidPeso molecolare:490.422FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Colore e forma:Odour Solid
